$7.90
0.49[6.61%]
At close: Apr 17
$7.90
0[0.00%]
PreMarket: 4:09PM EDT
IGM Biosciences
(NASDAQ:IGMS)IGM Biosciences Stock (NASDAQ:IGMS), Analyst Ratings, Price Targets, Predictions
IGM Biosciences Inc has a consensus price target of $29.23, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and RBC Capital on April 18, 2024, March 12, 2024, and March 8, 2024. With an average price target of $15 between HC Wainwright & Co., HC Wainwright & Co., and RBC Capital, there's an implied 89.87% upside for IGM Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
Wedbush
B of A Securities
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for IGM Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | IGMS | Buy Now | IGM Biosciences | $7.90 | 51.9% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 03/12/2024 | IGMS | Buy Now | IGM Biosciences | $7.90 | 51.9% | HC Wainwright & Co. | Robert Burns | $7 → $12 | Maintains | Neutral | Get Alert |
| 03/08/2024 | IGMS | Buy Now | IGM Biosciences | $7.90 | 165.82% | RBC Capital | Brian Abrahams | → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | IGMS | Buy Now | IGM Biosciences | $7.90 | 153.16% | Wedbush | Robert Driscoll | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 02/09/2024 | IGMS | Buy Now | IGM Biosciences | $7.90 | 165.82% | RBC Capital | Brian Abrahams | $9 → $21 | Upgrade | Sector Perform → Outperform | Get Alert |
| 12/15/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 1.27% | B of A Securities | Geoff Meacham | → $8 | Downgrade | Buy → Neutral | Get Alert |
| 12/07/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | -11.39% | HC Wainwright & Co. | Robert Burns | $11 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 12/06/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 13.92% | RBC Capital | Brian Abrahams | $8 → $9 | Maintains | Sector Perform | Get Alert |
| 11/15/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 1.27% | Morgan Stanley | Michael Lapides | $15 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/15/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 39.24% | HC Wainwright & Co. | Robert Burns | $17 → $11 | Maintains | Buy | Get Alert |
| 11/14/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 216.46% | Stifel | Stephen Willey | $26 → $25 | Maintains | Buy | Get Alert |
| 11/14/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 1.27% | RBC Capital | Brian Abrahams | $11 → $8 | Maintains | Sector Perform | Get Alert |
| 09/06/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 216.46% | Truist Securities | Asthika Goonewardene | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 39.24% | RBC Capital | Brian Abrahams | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/07/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | — | Needham | Matt McGinley | — | Downgrade | Buy → Hold | Get Alert |
| 08/07/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 115.19% | HC Wainwright & Co. | Robert Burns | $22 → $17 | Maintains | Buy | Get Alert |
| 08/07/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 89.87% | Morgan Stanley | Michael Lapides | $20 → $15 | Maintains | Equal-Weight | Get Alert |
| 06/06/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 178.48% | HC Wainwright & Co. | Robert Burns | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | IGMS | Buy Now | IGM Biosciences | $7.90 | 368.35% | Wedbush | Robert Driscoll | → $37 | Reiterates | Outperform → Outperform | Get Alert |
FAQ
What is the target price for IGM Biosciences (IGMS)?
The latest price target for IGM Biosciences (NASDAQ: IGMS) was reported by HC Wainwright & Co. on April 18, 2024. The analyst firm set a price target for $12.00 expecting IGMS to rise to within 12 months (a possible 51.90% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IGM Biosciences (IGMS)?
The latest analyst rating for IGM Biosciences (NASDAQ: IGMS) was provided by HC Wainwright & Co., and IGM Biosciences reiterated their neutral rating.
When was the last upgrade for IGM Biosciences (IGMS)?
The last upgrade for IGM Biosciences Inc happened on February 9, 2024 when RBC Capital raised their price target to $21. RBC Capital previously had a sector perform for IGM Biosciences Inc.
When was the last downgrade for IGM Biosciences (IGMS)?
The last downgrade for IGM Biosciences Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $8 for IGM Biosciences Inc.
When is the next analyst rating going to be posted or updated for IGM Biosciences (IGMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGM Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGM Biosciences was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating IGM Biosciences (IGMS) correct?
While ratings are subjective and will change, the latest IGM Biosciences (IGMS) rating was a reiterated with a price target of $0.00 to $12.00. The current price IGM Biosciences (IGMS) is trading at is $7.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.